tiprankstipranks
Advertisement
Advertisement

AU:PYC Stock Latest News

PYC’s VP-001 Eye Trial Reaches Phase 1 Finish Line, Setting Up the Next Investment Milestone
Company AnnouncementsPYC’s VP-001 Eye Trial Reaches Phase 1 Finish Line, Setting Up the Next Investment Milestone
13d ago
PYC
PYC Therapeutics Nears an Inflection Point With Completion of Its VP-001 Retinal Trial
PremiumCompany Announcements
PYC Therapeutics Nears an Inflection Point With Completion of Its VP-001 Retinal Trial
13d ago
PYC
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
PremiumCompany Announcements
PYC Therapeutics Resets CEO Pay to Sharpen Market Alignment and Performance Focus
16d ago
PYC
PYC Therapeutics outlines limits of data and risk profile in investor update
PremiumCompany Announcements
PYC Therapeutics outlines limits of data and risk profile in investor update
21d ago
PYC
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
PremiumCompany Announcements
PYC Therapeutics Cuts Option Overhang as Multiple Incentive Securities Lapse
1M ago
PYC
PYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
PremiumCompany AnnouncementsPYC to unveil early clinical data on first-in-class gene-targeted eye drugs at ARVO
1M ago
PYC
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
Premium
Company Announcements
PYC Therapeutics Issues New Shares Following Option Exercise and Lodges Cleansing Notice
1M ago
PYC
PYC Therapeutics Lists Additional 250,000 Shares on ASX
Premium
Company Announcements
PYC Therapeutics Lists Additional 250,000 Shares on ASX
1M ago
PYC
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
PremiumCompany Announcements
PYC Therapeutics Advances Genetic Disease Pipeline After $600m Capital Raise
1M ago
PYC
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
PremiumCompany Announcements
PYC Wins EMA Orphan Status for RP11 Gene Therapy Candidate VP-001
2M ago
PYC
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
PremiumCompany Announcements
PYC Therapeutics Wins Safety Nod to Advance ADOA Drug PYC-001 to Multi-Dose Trial
2M ago
PYC
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
PremiumCompany Announcements
PYC Therapeutics CEO Increases Shareholding and Receives Major Option Grant
3M ago
PYC
PYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
PremiumCompany AnnouncementsPYC Therapeutics to Showcase PKD Drug Progress at World Nephrology Congress
3M ago
PYC
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
Premium
Company Announcements
PYC Therapeutics Advances ADOA Drug PYC-001 With New Clinical Data and Ongoing Trial
3M ago
PYC
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
Premium
Ratings
PYC Therapeutics: Strengthened Balance Sheet and Expanded Development Plan Underpin Continued Buy Rating
3M ago
PYC Therapeutics CEO Increases Shareholding and Awaits Approval for New Options Grant
PremiumCompany Announcements
PYC Therapeutics CEO Increases Shareholding and Awaits Approval for New Options Grant
3M ago
PYC
PYC Therapeutics Seeks ASX Quotation for Over 10.5 Million New Shares
PremiumCompany Announcements
PYC Therapeutics Seeks ASX Quotation for Over 10.5 Million New Shares
3M ago
PYC
PYC Therapeutics Seeks ASX Quotation for Over 31 Million New Shares
PremiumCompany Announcements
PYC Therapeutics Seeks ASX Quotation for Over 31 Million New Shares
3M ago
PYC
PYC Therapeutics appoints new joint company secretary to oversee ASX compliance
PremiumCompany Announcements
PYC Therapeutics appoints new joint company secretary to oversee ASX compliance
3M ago
PYC
PYC Therapeutics Completes $47m Retail Entitlement Offer, Boosting Capital for RNA Programs
PremiumCompany AnnouncementsPYC Therapeutics Completes $47m Retail Entitlement Offer, Boosting Capital for RNA Programs
3M ago
PYC
PYC Therapeutics Issues Cautious Q1 2026 Investor Update
Premium
Company Announcements
PYC Therapeutics Issues Cautious Q1 2026 Investor Update
4M ago
PYC
PYC Therapeutics Files Interim Results as RNA Pipeline Advances
Premium
Company Announcements
PYC Therapeutics Files Interim Results as RNA Pipeline Advances
4M ago
PYC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >